about
Mechanical oscillations enhance gene delivery into suspended cells.Direct cytosolic delivery of siRNA using nanoparticle-stabilized nanocapsulesLipid-based vectors for siRNA deliveryNucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.FUNCTIONAL NANOPARTICLES FOR MOLECULAR IMAGING GUIDED GENE DELIVERYIn Silico, In Vitro, and In Vivo Studies Indicate the Potential Use of Bolaamphiphiles for Therapeutic siRNAs DeliveryIn vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Chitosan hydrogel as siRNA vector for prolonged gene silencing.Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.MicroRNA delivery by cationic lipoplexes for lung cancer therapy.Human-protein-derived peptides for intracellular delivery of biomolecules.Recent In Vivo Evidences of Particle-Based Delivery of Small-Interfering RNA (siRNA) into Solid TumorsLipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery.A novel in vivo siRNA delivery system specifically targeting liver cells for protection of ConA-induced fulminant hepatitisNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Multistage nanoparticle delivery system for deep penetration into tumor tissue.Multifunctional triblock Nanocarrier (PAMAM-PEG-PLL) for the efficient intracellular siRNA delivery and gene silencing.Delivering nanomedicine to solid tumors.CRACC-CRACC interaction between Kupffer and NK cells contributes to poly I:C/D-GalN induced hepatitis.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.Red-luminescent europium (III) doped silica nanoshells: synthesis, characterization, and their interaction with HeLa cells.In vitro evaluation of optimized liposomes for delivery of small interfering RNA.Cationic additives in nanosystems activate cytotoxicity and inflammatory response of human neutrophils: lipid nanoparticles versus polymeric nanoparticles.Combinatorial library strategies for synthesis of cationic lipid-like nanoparticles and their potential medical applications.Delivery of siRNA to the mouse lung via a functionalized lipopolyamine.Nanoparticle-mediated down-regulation of TWIST increases radiosensitivity of nasopharyngeal carcinoma cells via ERK pathwayDegradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media.Inhibition of liver fibrosis using vitamin A-coupled liposomes to deliver matrix metalloproteinase-2 siRNA in vitro.Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells.Europium Doped TiO(2) Hollow Nanoshells: Two-Photon Imaging of Cell Binding.Effect of surface properties on liposomal siRNA delivery.Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery.Toward personalized cancer nanomedicine - past, present, and future.Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy.Managing diabetes with nanomedicine: challenges and opportunitiesCircularized synthetic oligodeoxynucleotides serve as promoterless RNA polymerase III templates for small RNA generation in human cells.Melittin derived peptides for nanoparticle based siRNA transfection.Synthesis, characterization, and evaluation of ionizable lysine-based lipids for siRNA deliveryThe small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.
P2860
Q27333643-7B064B6B-31B7-4F50-8938-C3E0820FAC02Q27339704-D090EAC3-846B-4924-8402-9F597DC6A770Q28828356-2614E76F-8773-4A42-834B-9B5B87F14AB7Q30434521-A6A37387-D358-4DFB-8070-866BB6FE5ACFQ30472645-3BACB9A0-D5D2-4328-80E4-A32F549A5C16Q30538383-1E7322E2-63DA-4642-A3C5-F52E4C11A27CQ33765102-F6DEF384-73EB-4E6A-840F-4AC167316211Q33830955-35A62517-3B77-47FB-8A25-E252F1A5D146Q33925196-25D082A3-28F8-48B2-8F06-54BED43C45FFQ33935474-BC401F02-6938-4733-9AE8-F060ED4CEFBBQ34060310-64579368-E2CC-45F3-8C25-0B066150EA23Q34093882-F3B32E8A-0BA8-4D8A-94E9-605AB05A7080Q34165321-82054824-A189-4CFD-B614-5C543501F620Q34197336-8BA495F4-4EC9-40DD-A2F5-9C6A39B0EE00Q34412219-25E55ECB-E219-42ED-8FDB-839C8D43F906Q34534023-CADF3C59-F8EA-40FB-B6E1-EEA8629E204AQ34572820-4AD6188F-2FD4-4F2F-8789-7AA45EAC22E9Q34707568-2BEB452B-9C8B-4EB3-894E-D11415F3C82DQ34726981-0406288F-313F-4F7B-8B91-F226824463AFQ35010377-D57DA7D6-4963-4501-87F9-0695901F0583Q35093966-C1B707C9-F234-4172-8740-79DB7549297CQ35097866-00B389A3-1034-4056-B589-3E029584CED2Q35140847-D09ACB57-9014-4918-B1FD-8383F60634B8Q35547044-05705871-E1EF-4208-B6F3-0CE8A70A1528Q35568750-44CCFD43-E2E8-45EE-84CC-77EA78CE08FFQ35665154-C3803FE7-CDB5-4112-8E95-ED420E5B7548Q35758037-5CFA46EC-E4B7-4C41-A816-83496C17C3F1Q35867148-A8A6AD45-C944-4675-83D1-80D475088D06Q35919793-01C196FA-C69D-4835-BDE3-2A4E7D9066DFQ36170747-3B23F35D-D38F-4AD3-9E9D-683E2E291741Q36419412-6D7E5F8A-C5A2-43CF-B713-F08025BB3A29Q36421379-B296D478-4EF0-43A8-8B3F-EACF197EB397Q36448811-7F7F2339-51FB-4B7A-A4E6-B95D62C32A59Q36472802-592C59ED-1598-4EA8-B044-560AEE4FFFD5Q36510849-71BC5C53-E3CA-4E21-B5AC-1DDD341740ECQ36574654-95C9DBED-B319-498B-B430-67992277D167Q36619965-296EF46A-2460-4E37-BC86-E59A708E6CABQ36626455-270181CD-E42F-40F1-81B8-270CB75A84FFQ36651464-53EFFE5B-D1E4-4581-AFC0-ED38AC7BA459Q36740806-25822BD2-E17B-4EDC-B97D-CCAC3F11AC71
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipid-based nanotherapeutics for siRNA delivery
@en
Lipid-based nanotherapeutics for siRNA delivery.
@nl
type
label
Lipid-based nanotherapeutics for siRNA delivery
@en
Lipid-based nanotherapeutics for siRNA delivery.
@nl
prefLabel
Lipid-based nanotherapeutics for siRNA delivery
@en
Lipid-based nanotherapeutics for siRNA delivery.
@nl
P2093
P2860
P1476
Lipid-based nanotherapeutics for siRNA delivery
@en
P2093
A Schroeder
C G Levins
D G Anderson
P2860
P356
10.1111/J.1365-2796.2009.02189.X
P407
P577
2010-01-01T00:00:00Z